Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 47 clinical trials
Dapagliflozin Plus Pioglitazone in T1DM

demonstrate that the addition of pioglitazone to SGLT2 inhibitor in T1DM patients produces greater reduction in the HbA1c without increasing risk of ketoacidosis and hypoglycemia.

dapagliflozin
ketoacidosis
hypoglycemia
poor glycaemic control
insulin
  • 51 views
  • 14 Feb, 2021
  • 1 location
Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity

> Dapagliflozin plus metformin XR is a medicine composed with an oral antidiabetic of the group of inhibitors of SGLT2 that has shown to have significant side effects in the weight reduction and visceral

antidiabetic agents
diabetes
body mass index
dyslipidemia
type 2 diabetes mellitus
  • 25 views
  • 05 May, 2021
  • 2 locations
Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .

which mechanisms are underlying apart from SGLT2 inhibition. In addition, the impact of dapagliflozin on cardiac remodeling parameters, as assessed by echocardiography and biomarkers, is not well

  • 0 views
  • 19 Feb, 2021
  • 1 location
Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients

in the HbA1c , which was significantly greater than that caused by other classes of antidiabetic agents (e.g. DPP4 inhibitors, and SGLT2 inhibitors). Members of this class of drugs exert multiple

plasma glucose
glucagon-like peptide 1
antidiabetic agents
sglt2 inhibitor
liraglutide
  • 0 views
  • 25 Jan, 2021
  • 1 location
Effectiveness of Dapagliflozin for Weight Loss

insulin. Dapagliflozin is a selective SGLT2 inhibitor than has shown a sustained effect on the reduction of glycated hemoglobin at 0.4 to 0.8 percent (initial 7.8 to 8.0 percent). Additionally

hypertension
apnea
prediabetic state
type 2 diabetes mellitus
insulin
  • 18 views
  • 25 Jan, 2021
  • 2 locations
Efficacy and Safety of Dapagliflozin in Acute Heart Failure

This is a randomized trial of the addition of dapagliflozin to patients with diabetes hospitalized with acute decompensated heart failure (ADHF). Participants will be recruited following an initial standard evaluation in the ED and randomized within 24 hours of presentation for ADHF in a 1:1 fashion to protocolized diuretic therapy …

loop diuretic
dapagliflozin
dyspnea
diuretics
congestion
  • 55 views
  • 24 Jan, 2021
  • 3 locations
Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial

The ATTEMPT (Adolescent Type 1 diabetes Treatment with SGLT2i for hyperglycEMia & hyPerfilTration Trial) is a multi-center, double-blinded, randomized, placebo-controlled trial to evaluate the effect of treatment with Dapagliflozin when compared to placebo, in combination with adjustable insulin, on measured GFR in adolescents with T1D 12 to <19 years of …

  • 0 views
  • 27 Jan, 2021
  • 3 locations
Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin

The objectives of this study are 1) to compare the effect of ipragliflozin 50 mg on glucose-lowering effect with sitagliptin 100 mg in patients with type 2 diabetes mellitus, whose HbA1c level is 7.5% with sulfonylurea and metformin, 2) to investigate changes of other metabolic and cardiovascular risk factors such …

gliclazide
sulfonylurea
sitagliptin 100 mg
sitagliptin
glimepiride
  • 8 views
  • 08 Apr, 2021
  • 1 location
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration

The investigators propose to treat newly diagnosed, hyperfiltering T2DM patients with or without microalbuminuria with dapagliflozin or metformin for 4 months. The metformin-treated group will serve as controls for improved glycemic control, since the investigators have shown that insulin therapy to normalize A1c reduces hyperfiltration and kidney size in T1DM …

glipizide
dapagliflozin
metformin
  • 217 views
  • 25 Jan, 2021
  • 6 locations
Atrasentan in Patients With Proteinuric Glomerular Diseases

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

  • 0 views
  • 17 Apr, 2021
  • 9 locations